Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 1
2006 1
2008 2
2009 2
2010 1
2011 4
2012 5
2013 6
2014 3
2015 7
2016 5
2017 5
2018 5
2019 4
2020 5
2021 4
2022 6
2023 7
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.
Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, Chan-Seng-Yue M, Voisin V, van Galen P, Tierens A, Cheok M, Preudhomme C, Dombret H, Daver N, Futreal PA, Minden MD, Kennedy JA, Wang JCY, Dick JE. Zeng AGX, et al. Among authors: tierens a. Nat Med. 2022 Jun;28(6):1212-1223. doi: 10.1038/s41591-022-01819-x. Epub 2022 May 26. Nat Med. 2022. PMID: 35618837
Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia.
Kim JC, Chan-Seng-Yue M, Ge S, Zeng AGX, Ng K, Gan OI, Garcia-Prat L, Flores-Figueroa E, Woo T, Zhang AXW, Arruda A, Chithambaram S, Dobson SM, Khoo A, Khan S, Ibrahimova N, George A, Tierens A, Hitzler J, Kislinger T, Dick JE, McPherson JD, Minden MD, Notta F. Kim JC, et al. Among authors: tierens a. Nat Genet. 2023 Jul;55(7):1186-1197. doi: 10.1038/s41588-023-01429-4. Epub 2023 Jun 19. Nat Genet. 2023. PMID: 37337105 Free PMC article.
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.
van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fernández Navarro JM, Gerbing RB, Goemans BF, de Groot-Kruseman HA, Guest E, Ha SY, Hasle H, Kelaidi C, Lapillonne H, Leverger G, Locatelli F, Masetti R, Miyamura T, Norén-Nyström U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan CM, Kaspers GJL. van Weelderen RE, et al. Among authors: tierens a. J Clin Oncol. 2023 Jun 1;41(16):2963-2974. doi: 10.1200/JCO.22.02120. Epub 2023 Mar 30. J Clin Oncol. 2023. PMID: 36996387 Free PMC article.
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.
van Weelderen RE, Harrison CJ, Klein K, Jiang Y, Abrahamsson J, Alonzo T, Aplenc R, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fernández Navarro JM, Gamis A, Gerbing RB, Goemans BF, de Groot-Kruseman HA, Guest E, Ha SY, Hasle H, Kelaidi C, Lapillonne H, Leverger G, Locatelli F, Miyamura T, Norén-Nyström U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan CM, Kaspers GJL. van Weelderen RE, et al. Among authors: tierens a. Blood Adv. 2024 Jun 25;8(12):3200-3213. doi: 10.1182/bloodadvances.2023011771. Blood Adv. 2024. PMID: 38621200
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.
Davidson MB, Kennedy JA, Capo-Chichi JM, Shi Y, Xu W, Cheung V, Arruda A, Bankar A, Richard-Carpentier G, Chan S, Maze D, Minden MD, Schimmer AD, Schuh AC, Sibai H, Yee K, Tierens A, Viswabandya A, Gupta V. Davidson MB, et al. Among authors: tierens a. Blood Adv. 2024 Mar 12;8(5):1281-1294. doi: 10.1182/bloodadvances.2023011735. Blood Adv. 2024. PMID: 38170760 Free PMC article.
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Lucero J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, Stockley T, Gupta V, Bankar A, Chan S, Schuh AC, Minden M, Mattsson J, Kumar R, Sibai H, Tierens A, Kim DDH. Lucero J, et al. Among authors: tierens a. Ann Hematol. 2024 Apr;103(4):1187-1196. doi: 10.1007/s00277-024-05639-6. Epub 2024 Jan 30. Ann Hematol. 2024. PMID: 38291275
76 results